Sheffield Pharmaceuticals, LLC

Belkins
We are a Connecticut-based contract manufacturer and supplier of store brand OTC products to the largest retailers and drug store chains in the USA. We are the home of Dr. Sheffield and exclusive branded products that offer excellent quality, value and efficacy to promote wellness and to help reduce suffering. We service the over-the-counter (OTC) cream, ointment and toothpaste, nasal and first aid segments with products that are made in the USA since 1850.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MOVILITAS.CLOUD™ VRS SOLUTION CLARIFIES DSCSA VERIFICATION FOR PHARMACEUTICAL WHOLESALE DISTRIBUTORS AND MANUFACTURERS

Movilitas | July 13, 2020

news image

Movilitas announced today the availability of its Movilitas.Cloud™ Verification Router Service (VRS) solution that simplifies the verification process and compliance for pharmaceutical wholesale distributors and manufacturers. The new mobile app provides an out-of-the-box solution for the November 2020 Drug Supply Chain Security Act (DSCSA) saleable returns verification deadline. With the upcoming regulation, wholesale distributors must verify the serialized product identifi...

Read More

PHARMA TECH

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

news image

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

news image

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More

RESEARCH

STALLERGENES GREER AND APTAR PHARMA ANNOUNCE PARTNERSHIP TO DEVELOP NOVEL CONNECTED DEVICE FOR ALLERGEN IMMUNOTHERAPY TREATMENT DELIVERY

STALLERGENES GREER LTD | October 27, 2021

news image

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions. “This exclusive partn...

Read More
news image

MOVILITAS.CLOUD™ VRS SOLUTION CLARIFIES DSCSA VERIFICATION FOR PHARMACEUTICAL WHOLESALE DISTRIBUTORS AND MANUFACTURERS

Movilitas | July 13, 2020

Movilitas announced today the availability of its Movilitas.Cloud™ Verification Router Service (VRS) solution that simplifies the verification process and compliance for pharmaceutical wholesale distributors and manufacturers. The new mobile app provides an out-of-the-box solution for the November 2020 Drug Supply Chain Security Act (DSCSA) saleable returns verification deadline. With the upcoming regulation, wholesale distributors must verify the serialized product identifi...

Read More
news image

PHARMA TECH

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More
news image

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More
news image

RESEARCH

STALLERGENES GREER AND APTAR PHARMA ANNOUNCE PARTNERSHIP TO DEVELOP NOVEL CONNECTED DEVICE FOR ALLERGEN IMMUNOTHERAPY TREATMENT DELIVERY

STALLERGENES GREER LTD | October 27, 2021

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions. “This exclusive partn...

Read More